CL2007002930A1 - Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati - Google Patents
Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferatiInfo
- Publication number
- CL2007002930A1 CL2007002930A1 CL200702930A CL2007002930A CL2007002930A1 CL 2007002930 A1 CL2007002930 A1 CL 2007002930A1 CL 200702930 A CL200702930 A CL 200702930A CL 2007002930 A CL2007002930 A CL 2007002930A CL 2007002930 A1 CL2007002930 A1 CL 2007002930A1
- Authority
- CL
- Chile
- Prior art keywords
- monohidratado
- hyperproliferati
- carbonxamide
- fluorofenoxi
- methylpiridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06021296 | 2006-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002930A1 true CL2007002930A1 (es) | 2008-04-04 |
Family
ID=38972960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702930A CL2007002930A1 (es) | 2006-10-11 | 2007-10-11 | Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati |
Country Status (38)
Country | Link |
---|---|
US (3) | US9957232B2 (es) |
EP (1) | EP2097381B1 (es) |
JP (1) | JP5346293B2 (es) |
KR (1) | KR101418623B1 (es) |
CN (1) | CN101547903B (es) |
AR (1) | AR062927A1 (es) |
AU (1) | AU2007306716B2 (es) |
BR (1) | BRPI0719828B1 (es) |
CA (1) | CA2666170C (es) |
CL (1) | CL2007002930A1 (es) |
CO (1) | CO6150132A2 (es) |
CR (1) | CR10663A (es) |
CY (1) | CY1114637T1 (es) |
DK (1) | DK2097381T3 (es) |
ES (1) | ES2427358T3 (es) |
GT (1) | GT200900057A (es) |
HK (1) | HK1136287A1 (es) |
HN (1) | HN2009000499A (es) |
IL (1) | IL197369A (es) |
JO (1) | JO3021B1 (es) |
MA (1) | MA30878B1 (es) |
MX (1) | MX2009002642A (es) |
MY (1) | MY152595A (es) |
NZ (1) | NZ576153A (es) |
PA (1) | PA8750301A1 (es) |
PE (1) | PE20081459A1 (es) |
PL (1) | PL2097381T3 (es) |
PT (1) | PT2097381E (es) |
RU (1) | RU2466992C2 (es) |
SG (1) | SG175584A1 (es) |
SI (1) | SI2097381T1 (es) |
SV (1) | SV2009003187A (es) |
TN (1) | TN2009000072A1 (es) |
TW (1) | TWI428322B (es) |
UA (1) | UA95984C2 (es) |
UY (1) | UY30633A1 (es) |
WO (1) | WO2008043446A1 (es) |
ZA (1) | ZA200902469B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1636585T3 (da) * | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
EP1797038B1 (en) * | 2004-09-29 | 2012-06-13 | Bayer Pharma Aktiengesellschaft | Thermodynamically stable form of bay 43-9006 tosylate |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
EP2089363A1 (en) * | 2006-11-14 | 2009-08-19 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
AU2015201426B2 (en) * | 2010-04-15 | 2016-07-07 | Bayer Healthcare Llc | Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate |
AR081060A1 (es) * | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
WO2012012404A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
AP2013006834A0 (en) | 2010-10-01 | 2013-04-30 | Bayer Ip Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
EA201400064A1 (ru) | 2011-06-28 | 2014-05-30 | Байер Хелфкеэ Ллк | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб |
UY35006A (es) | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
DK2900269T3 (en) | 2012-09-25 | 2018-10-01 | Bayer Pharma AG | COMBINATION OF REGORAFENIB AND ACETYLSALICYLIC ACID FOR TREATMENT OF COLORECTAL CANCER. |
UY35183A (es) | 2012-12-21 | 2014-07-31 | Bayer Healthcare Llc | Composición farmacéutica oftalmológica tópica que contiene regorafenib |
US9518020B2 (en) * | 2013-10-04 | 2016-12-13 | Hetero Research Foundation | Process for Regorafenib |
CN103923000A (zh) * | 2014-01-29 | 2014-07-16 | 苏州晶云药物科技有限公司 | 几种新晶型及其制备方法 |
CN104829523B (zh) * | 2014-04-30 | 2017-10-31 | 药源药物化学(上海)有限公司 | 瑞戈非尼盐及其晶型、制备方法 |
WO2016005874A1 (en) | 2014-07-09 | 2016-01-14 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
WO2016038590A1 (en) | 2014-09-12 | 2016-03-17 | Mylan Laboratories Ltd | Process for the preparation of crystalline form i of regorafenib |
CN104546776B (zh) * | 2015-02-10 | 2017-08-22 | 杭州朱养心药业有限公司 | 瑞戈非尼片剂药物组合物和制法 |
CN105985287B (zh) * | 2015-02-13 | 2018-07-17 | 上海京新生物医药有限公司 | 一种瑞戈非尼新晶型 |
CN107118153A (zh) * | 2016-02-25 | 2017-09-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种瑞戈非尼一水合物晶型及其制备方法 |
CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
FI3630112T3 (fi) | 2017-06-02 | 2024-05-02 | Bayer Healthcare Llc | Regorafenibin ja nivolumabin yhdistelmä syövän hoidossa |
EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
WO2021160708A1 (en) | 2020-02-14 | 2021-08-19 | Bayer Aktiengesellschaft | Combination of regorafenib and msln-ttc for treating cancer |
CN111995571B (zh) * | 2020-08-07 | 2021-12-03 | 天津理工大学 | 一种瑞戈非尼与马来酸的共晶及其制备方法 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6705789A (es) | 1967-03-08 | 1968-09-09 | ||
US4223153A (en) | 1979-02-09 | 1980-09-16 | Eli Lilly And Company | Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
NZ220764A (en) * | 1986-07-02 | 1989-09-27 | Shionogi & Co | Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions |
US4835180A (en) * | 1986-10-02 | 1989-05-30 | Sterling Drug Inc. | N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity |
US5011472A (en) * | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5629425A (en) * | 1994-09-19 | 1997-05-13 | Eli Lilly And Company | Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene |
CO4410190A1 (es) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO |
AU1153097A (en) * | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
NZ334346A (en) | 1996-09-23 | 2000-05-26 | Lilly Co Eli | Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders |
US6344476B1 (en) * | 1997-05-23 | 2002-02-05 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US20120046290A1 (en) * | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
RU2319693C9 (ru) * | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US8124630B2 (en) * | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1158985B1 (en) * | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
IN190389B (es) * | 1999-07-14 | 2003-07-26 | Ranbaxy Lab Ltd | |
NZ519984A (en) | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
DK2305255T3 (da) * | 2001-12-03 | 2012-12-10 | Bayer Healthcare Llc | Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
ATE529406T1 (de) * | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
US7928277B1 (en) * | 2002-02-11 | 2011-04-19 | Cox Jr Henry Wilmore | Method for reducing contamination |
AU2003209119A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
US20060034797A1 (en) * | 2002-05-03 | 2006-02-16 | Arien Albertina M E | Polymeric micromulsions |
UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
DK1636585T3 (da) * | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
CL2004001834A1 (es) * | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
EP1678123A1 (en) * | 2003-10-15 | 2006-07-12 | Bayer HealthCare AG | Tetrahydro-naphthalene and urea derivatives |
TWI338004B (en) | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
CN101010315A (zh) * | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
CN101048140B (zh) * | 2004-08-27 | 2013-06-19 | 拜尔保健公司 | 用于治疗癌症的药物组合物 |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
EP1797038B1 (en) * | 2004-09-29 | 2012-06-13 | Bayer Pharma Aktiengesellschaft | Thermodynamically stable form of bay 43-9006 tosylate |
UA90691C2 (en) * | 2004-09-29 | 2010-05-25 | Баер Шеринг Фарма Акциенгезельшафт | Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide |
CN101132779B (zh) * | 2005-03-07 | 2016-03-16 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
CA2609389A1 (en) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment |
US20090306020A1 (en) * | 2005-05-27 | 2009-12-10 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
WO2007047955A2 (en) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
WO2007053573A2 (en) * | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Treatment of cancer with sorafenib |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
US20090068146A1 (en) * | 2005-10-31 | 2009-03-12 | Scott Wilhelm | Diaryl ureas and combinations |
CN101351709A (zh) * | 2005-11-02 | 2009-01-21 | 拜尔健康护理有限责任公司 | 癌症的预测和预后以及监控癌症治疗的方法 |
EP1948176B1 (en) * | 2005-11-10 | 2011-01-05 | Bayer Schering Pharma Aktiengesellschaft | Diaryl ureas for treating pulmonary hypertension |
JP5084736B2 (ja) * | 2005-11-10 | 2012-11-28 | バイエル・ファルマ・アクチェンゲゼルシャフト | 肺高血圧を処置するためのジアリールウレア |
WO2007059154A2 (en) * | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
BRPI0618597A2 (pt) * | 2005-11-14 | 2011-09-06 | Bayer Healthcare Llc | métodos de predição e prognóstico de cáncer e método de monitoramento de terapia contra o cáncer |
MX2008006979A (es) * | 2005-12-01 | 2009-01-14 | Bayer Healthcare Llc | Compuestos de urea utiles en el tratamiento contra el cancer. |
JP2009519265A (ja) * | 2005-12-15 | 2009-05-14 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ウイルス感染を処置するためのジアリールウレア |
US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
JP2009524585A (ja) * | 2005-12-15 | 2009-07-02 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ウイルス感染を処置するためのジアリールウレア |
JP5331485B2 (ja) * | 2005-12-21 | 2013-10-30 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 癌および他の障害の処置に有用な置換ピリミジン誘導体 |
WO2007139930A2 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
EP2081902A1 (en) * | 2006-11-09 | 2009-07-29 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
EP2089363A1 (en) * | 2006-11-14 | 2009-08-19 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide |
ATE528286T1 (de) * | 2006-12-20 | 2011-10-15 | Bayer Healthcare Llc | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs |
EP2111401B1 (en) * | 2006-12-20 | 2011-02-16 | Bayer HealthCare, LLC | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
EP2114403A2 (en) * | 2007-01-19 | 2009-11-11 | Bayer Healthcare, LLC | Treatment of cancers having resistance to chemotherapeutic agents |
US8680124B2 (en) * | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
EP2231612A1 (en) * | 2008-01-17 | 2010-09-29 | Sicor, Inc. | Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof |
WO2009156070A1 (en) * | 2008-06-25 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
CA2741087A1 (en) * | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
EP2480535A1 (en) * | 2009-09-24 | 2012-08-01 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
EP2499116A1 (en) * | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
WO2011146725A1 (en) | 2010-05-19 | 2011-11-24 | Bayer Healthcare Llc | Biomarkers for a multikinase inhibitor |
WO2012012404A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
-
2007
- 2007-09-20 AR ARP070104168A patent/AR062927A1/es unknown
- 2007-09-29 KR KR1020097007422A patent/KR101418623B1/ko active IP Right Review Request
- 2007-09-29 AU AU2007306716A patent/AU2007306716B2/en active Active
- 2007-09-29 DK DK07818583.2T patent/DK2097381T3/da active
- 2007-09-29 CA CA2666170A patent/CA2666170C/en active Active
- 2007-09-29 JP JP2009531733A patent/JP5346293B2/ja active Active
- 2007-09-29 PT PT78185832T patent/PT2097381E/pt unknown
- 2007-09-29 BR BRPI0719828-0A patent/BRPI0719828B1/pt active IP Right Grant
- 2007-09-29 SI SI200731313T patent/SI2097381T1/sl unknown
- 2007-09-29 SG SG2011071990A patent/SG175584A1/en unknown
- 2007-09-29 MX MX2009002642A patent/MX2009002642A/es active IP Right Grant
- 2007-09-29 EP EP07818583.2A patent/EP2097381B1/en active Active
- 2007-09-29 WO PCT/EP2007/008503 patent/WO2008043446A1/en active Application Filing
- 2007-09-29 NZ NZ576153A patent/NZ576153A/en unknown
- 2007-09-29 ES ES07818583T patent/ES2427358T3/es active Active
- 2007-09-29 US US12/444,974 patent/US9957232B2/en active Active
- 2007-09-29 MY MYPI20091350 patent/MY152595A/en unknown
- 2007-09-29 UA UAA200904623A patent/UA95984C2/ru unknown
- 2007-09-29 RU RU2009117388/04A patent/RU2466992C2/ru active
- 2007-09-29 CN CN200780037680.2A patent/CN101547903B/zh active Active
- 2007-09-29 PL PL07818583T patent/PL2097381T3/pl unknown
- 2007-10-07 JO JOP/2007/0423A patent/JO3021B1/ar active
- 2007-10-08 UY UY30633A patent/UY30633A1/es not_active Application Discontinuation
- 2007-10-09 TW TW096137745A patent/TWI428322B/zh active
- 2007-10-10 PA PA20078750301A patent/PA8750301A1/es unknown
- 2007-10-10 PE PE2007001368A patent/PE20081459A1/es not_active Application Discontinuation
- 2007-10-11 CL CL200702930A patent/CL2007002930A1/es unknown
-
2009
- 2009-02-27 TN TN2009000072A patent/TN2009000072A1/fr unknown
- 2009-03-03 IL IL197369A patent/IL197369A/en active IP Right Grant
- 2009-03-11 CO CO09025191A patent/CO6150132A2/es unknown
- 2009-03-12 GT GT200900057A patent/GT200900057A/es unknown
- 2009-03-13 CR CR10663A patent/CR10663A/es unknown
- 2009-03-13 SV SV2009003187A patent/SV2009003187A/es unknown
- 2009-03-18 HN HN2009000499A patent/HN2009000499A/es unknown
- 2009-04-09 ZA ZA200902469A patent/ZA200902469B/xx unknown
- 2009-05-08 MA MA31857A patent/MA30878B1/fr unknown
-
2010
- 2010-03-24 HK HK10103082.1A patent/HK1136287A1/xx unknown
-
2013
- 2013-09-16 CY CY20131100798T patent/CY1114637T1/el unknown
-
2014
- 2014-05-14 US US14/277,095 patent/US20140315958A1/en not_active Abandoned
-
2018
- 2018-01-30 US US15/884,103 patent/US20180194730A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002930A1 (es) | Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati | |
BRPI0720637A2 (pt) | Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto | |
BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
BR122020011920A2 (pt) | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto | |
BRPI0819799A2 (pt) | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença | |
BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
BRPI0820665A2 (pt) | compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos | |
BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
CL2007002967A1 (es) | Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un | |
BRPI0607423A2 (pt) | forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto | |
BRPI0817200A2 (pt) | composições oftálmicas sólida e uso de compostos para fabricação de medicamento | |
BRPI0913585A2 (pt) | composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios | |
CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
BRPI0715531A2 (pt) | Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto | |
BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
BRPI0718587A2 (pt) | Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
BRPI0615163A2 (pt) | composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 | |
BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
CL2007000918A1 (es) | Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
BRPI1011768A2 (pt) | agentes para o tratamento e/ou profilaxia de um distúrbio, e de uma doença, composição farmacêutica, kit, derivado de tiazol, composto, combinação, e, uso de um derivado de tiazol |